FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2943036745> ?p ?o ?g. }

• W2943036745 abstract "Psoriasis and inflammatory bowel disease (IBD) are chronic inflammatory diseases with shared genetic susceptibility and immunologic aspects, mediated by the interleukin (IL)-23/IL-17 axis.1 Biologic therapies targeted against IL-17A and IL-17 receptor A have been associated with exacerbation of IBD both in clinical trials2-4 and real-world data.5 As IL-17 and IL-23 inhibitors act on the same inflammatory pathway, it is important to evaluate the effect of IL-23 inhibitors on IBD. Here, we examined the incidence of serious gastrointestinal (GI) disorders, specifically cases of IBD, including Crohn's disease and ulcerative colitis, reported during a phase 2b (P05495, NCT01225731) and 2 phase 3 (reSURFACE 1, NCT01722331; reSURFACE 2, NCT01729754) trials of tildrakizumab, an anti-IL-23p19 monoclonal antibody.6, 7 The trials included patients aged ≥18 years with moderate to severe chronic plaque psoriasis (body surface area involvement ≥10%, Physician's Global Assessment score ≥3, and Psoriasis Area and Severity Index score ≥12). Patients were randomized to receive subcutaneous placebo, tildrakizumab 100 mg or tildrakizumab 200 mg at Week 0, Week 4 and every 12 weeks thereafter. Full study details and results were published previously.6, 7 This post hoc analysis was based on data from all patients with exposure to placebo, tildrakizumab 100 mg or tildrakizumab 200 mg at any time during the base study period. All adverse events (AEs) were reviewed; exposure-adjusted incidence rates (number of events/100 patient-years) of serious GI AEs and cases of new onset or exacerbations of pre-existing IBD were compared across treatment groups. The analysis included 1911 patients from the three clinical trials, with a total exposure of 1927.19 patient-years for tildrakizumab and 218.86 patient-years for placebo. Across treatment groups, patients had similar pre-existing medical conditions (Table 1) and 15–19% of patients had pre-existing GI disorders (Table 1). The incidence of pre-existing IBD was low (family history was not recorded). In total, seven patients had a history of IBD: three patients had ulcerative colitis, 1 in each of the tildrakizumab and placebo groups; two patients had Crohn's disease, both from the tildrakizumab 200-mg group; and two patients had IBD (unclassified), both from the tildrakizumab 100-mg group. Serious GI AEs were infrequent and observed in one patient (0.46/100 patient-years) who received placebo, eight patients (0.80/100 patient-years) who received tildrakizumab 100 mg and four patients (0.43/100 patient-years) who received tildrakizumab 200 mg. There were no new cases of IBD or exacerbation of pre-existing IBD during the study. A summary of serious GI AEs is shown in Table 2. No individual event occurred in more than one patient across the treatment groups. This analysis suggests that the IL-23 inhibitor tildrakizumab does not induce or worsen IBD in patients with psoriasis. In contrast, clinical trials of IL-17 and IL-17 receptor A inhibitors showed occasional new cases and exacerbation of IBD in patients with psoriasis2 and in patients with Crohn's disease.3, 4 The differential effects might be explained by IL-23-independent production of IL-17A and the protective effect of IL-17A in the presence of epithelial injury, demonstrated in a preclinical model.8 These mechanistic hypotheses are validated by the positive results obtained with ustekinumab (IL-12/23 inhibitor) and risankizumab (IL-23 inhibitor) in clinical trials in patients with Crohn's disease.9, 10 Additional data on tildrakizumab from further clinical trials, clinical use and postmarketing surveillance are required to confirm the trial findings. Analyses and editorial support were funded by Sun Pharmaceutical Industries, Inc." @default.
• W2943036745 created "2019-05-09" @default.
• W2943036745 creator A5006526834 @default.
• W2943036745 creator A5025545596 @default.
• W2943036745 creator A5039474787 @default.
• W2943036745 creator A5051180916 @default.
• W2943036745 creator A5058734550 @default.
• W2943036745 creator A5070890272 @default.
• W2943036745 creator A5080223253 @default.
• W2943036745 date "2019-05-08" @default.
• W2943036745 modified "2023-09-27" @default.
• W2943036745 title "Incidence of serious gastrointestinal events among tildrakizumab‐treated patients with psoriasis" @default.
• W2943036745 cites W1836263069 @default.
• W2943036745 cites W2016080645 @default.
• W2943036745 cites W2077531651 @default.
• W2943036745 cites W2099687194 @default.
• W2943036745 cites W2132784721 @default.
• W2943036745 cites W2418506270 @default.
• W2943036745 cites W2494177319 @default.
• W2943036745 cites W2587065397 @default.
• W2943036745 cites W2606398981 @default.
• W2943036745 cites W2623888527 @default.
• W2943036745 cites W2809403868 @default.
• W2943036745 cites W4233817719 @default.
• W2943036745 doi "https://doi.org/10.1111/jdv.15643" @default.
• W2943036745 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6850306" @default.
• W2943036745 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31033068" @default.
• W2943036745 hasPublicationYear "2019" @default.
• W2943036745 type Work @default.
• W2943036745 sameAs 2943036745 @default.
• W2943036745 citedByCount "5" @default.
• W2943036745 countsByYear W29430367452019 @default.
• W2943036745 countsByYear W29430367452021 @default.
• W2943036745 countsByYear W29430367452022 @default.
• W2943036745 countsByYear W29430367452023 @default.
• W2943036745 crossrefType "journal-article" @default.
• W2943036745 hasAuthorship W2943036745A5006526834 @default.
• W2943036745 hasAuthorship W2943036745A5025545596 @default.
• W2943036745 hasAuthorship W2943036745A5039474787 @default.
• W2943036745 hasAuthorship W2943036745A5051180916 @default.
• W2943036745 hasAuthorship W2943036745A5058734550 @default.
• W2943036745 hasAuthorship W2943036745A5070890272 @default.
• W2943036745 hasAuthorship W2943036745A5080223253 @default.
• W2943036745 hasBestOaLocation W29430367451 @default.
• W2943036745 hasConcept C120665830 @default.
• W2943036745 hasConcept C121332964 @default.
• W2943036745 hasConcept C126322002 @default.
• W2943036745 hasConcept C142724271 @default.
• W2943036745 hasConcept C16005928 @default.
• W2943036745 hasConcept C197934379 @default.
• W2943036745 hasConcept C204787440 @default.
• W2943036745 hasConcept C27081682 @default.
• W2943036745 hasConcept C2776260265 @default.
• W2943036745 hasConcept C2777011040 @default.
• W2943036745 hasConcept C2777014857 @default.
• W2943036745 hasConcept C2778260677 @default.
• W2943036745 hasConcept C2779134260 @default.
• W2943036745 hasConcept C2779745271 @default.
• W2943036745 hasConcept C2779786854 @default.
• W2943036745 hasConcept C2780479503 @default.
• W2943036745 hasConcept C2780564577 @default.
• W2943036745 hasConcept C61511704 @default.
• W2943036745 hasConcept C71924100 @default.
• W2943036745 hasConcept C90924648 @default.
• W2943036745 hasConceptScore W2943036745C120665830 @default.
• W2943036745 hasConceptScore W2943036745C121332964 @default.
• W2943036745 hasConceptScore W2943036745C126322002 @default.
• W2943036745 hasConceptScore W2943036745C142724271 @default.
• W2943036745 hasConceptScore W2943036745C16005928 @default.
• W2943036745 hasConceptScore W2943036745C197934379 @default.
• W2943036745 hasConceptScore W2943036745C204787440 @default.
• W2943036745 hasConceptScore W2943036745C27081682 @default.
• W2943036745 hasConceptScore W2943036745C2776260265 @default.
• W2943036745 hasConceptScore W2943036745C2777011040 @default.
• W2943036745 hasConceptScore W2943036745C2777014857 @default.
• W2943036745 hasConceptScore W2943036745C2778260677 @default.
• W2943036745 hasConceptScore W2943036745C2779134260 @default.
• W2943036745 hasConceptScore W2943036745C2779745271 @default.
• W2943036745 hasConceptScore W2943036745C2779786854 @default.
• W2943036745 hasConceptScore W2943036745C2780479503 @default.
• W2943036745 hasConceptScore W2943036745C2780564577 @default.
• W2943036745 hasConceptScore W2943036745C61511704 @default.
• W2943036745 hasConceptScore W2943036745C71924100 @default.
• W2943036745 hasConceptScore W2943036745C90924648 @default.
• W2943036745 hasIssue "10" @default.
• W2943036745 hasLocation W29430367451 @default.
• W2943036745 hasLocation W29430367452 @default.
• W2943036745 hasLocation W29430367453 @default.
• W2943036745 hasLocation W29430367454 @default.
• W2943036745 hasOpenAccess W2943036745 @default.
• W2943036745 hasPrimaryLocation W29430367451 @default.
• W2943036745 hasRelatedWork W1200602752 @default.
• W2943036745 hasRelatedWork W2018010476 @default.
• W2943036745 hasRelatedWork W2069424104 @default.
• W2943036745 hasRelatedWork W2391106790 @default.
• W2943036745 hasRelatedWork W2887772216 @default.
• W2943036745 hasRelatedWork W3015166491 @default.
• W2943036745 hasRelatedWork W3025029990 @default.
• W2943036745 hasRelatedWork W3080588810 @default.
• W2943036745 hasRelatedWork W3084613618 @default.

• next